FindTrial
Sign In

A single-center randomized controlled study of esketamine combined with butorphanol versus butorphanol for perioperative analgesia and adverse reactions in patients undergoing elective general anesthesia thoracoscopic radical resection of lung cancer

A single-center randomized controlled study of esketamine combined with butorphanol versus butorphanol for perioperative analgesia and adverse reactions in patients undergoing elective general anesthesia thoracoscopic radical resection of lung cancer

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046939
Enrollment
Unknown
Registered
2021-05-31
Start date
2021-06-10
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1:Esketamine + Propofol
Group 2: Propofol

Sponsors

Beijing Cancer Control and Research Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years and <65 years; 2. ASA (American Society of Anesthesiologists) classification I-II; 3. BMI (Body Mass Index) 18-30kg/m^2; 4. No serious diseases of liver, kidney, heart, brain, lung and other important organs before operation; 5. No history of drug abuse; 6. Patients with no serious risk of blood pressure or increased intracranial pressure; 7. Patients with hypertension with good drug control (cuff blood pressure: resting systolic blood pressure / diastolic blood pressure lower than 180/100 mmHg); 8. Patients with normal liver and kidney function before surgery; 9. Patients undergoing elective general anesthesia thoracoscopic radical resection of lung cancer for the first time; 10. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients who are unwilling to undergo postoperative analgesia; 2. Patients who have participated in other clinical trials within the past four weeks; 3. Patients who cannot cooperate to complete the research plan, including those with language difficulties, infectious diseases or conscious disabilities; 4. Patients who are allergic to the active ingredients or excipients of esketamine or butorphanol.

Design outcomes

Primary

MeasureTime frame
Postoperative VAS score;—

Secondary

MeasureTime frame
Amount of analgesics administered intraoperatively and within 72 h after surgery;Postoperative ambulation time;Incidence of postoperative adverse effects;Anesthesia awakening time;Incidence of psychiatric adverse effects;Maintenance propofol and remifentanil dosage and hemodynamic parameters;Incidence of remedies;Level of satisfaction with anesthesia and analgesia;—

Countries

China

Contacts

Public ContactChen Jiheng

Beijing Cancer Control and Research Institute

2238165366@qq.com+86 13552694668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026